GW Pharmaceuticals Plc Stock News

GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid. Epidiolex still has a lot of growth potential in the short and long term, w

Vivien Azer Cowen Managing Director and Senior Research Analyst discusses the election day and the impact of cannabis legalization on stocks. #cannabis #marijuana #cannabislegalization Subscribe to Ya

GW Pharmaceuticals is an "underappreciated story," an analyst said as GWPH stock jumped higher on Wednesday for the second day running on better-than-expected third-quarter revenue. The post Cannabis

GW Pharmaceuticals (GWPH) news for Wednesday includes GWPH stock continuing to rise after the release of its Q3 earnings report yesterday. The post GW Pharmaceuticals News: Why GWPH Stock Is Running 2

GW Pharmaceuticals plc's (GWPH) CEO Justin Gover on Q3 2020 Results - Earnings Call Transcript

Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-base

The cannabinoid prescription drug Sativex has already been approved in numerous countries for reducing spasticity caused by MS.

Shares of GW Pharmaceuticals PLC rallied 4.7% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform reported a narrower-than-e

Shares of GW Pharmaceuticals PLC were indicated up more than 6% in premarket trading Tuesday, after the biopharmaceutical company developing therapeutics from its cannabinoid product platform said it

CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoi

Investors should study the various revenue streams for "epidiolex". Level of cash reserves important to judge likelihood of future share dilution.

Shares of Zogenix have been under pressure lately due to safety concerns surrounding its unique anti-epileptic drug, Fintepla.

The Global Dravet Syndrome Treatment Market will grow by $ 396.15 mn during 2020-2024

Today, our cannabis expert Don Yocham is going to talk about a biotech stock that’s delivered 1,000% in profits so far and show you what’s next…

Regulatory News: En avril 2020, Total (Paris:FP) (LSE:TTA) (NYSE:TOT) et AGEL, filiale d’énergies renouvelables du Groupe Adani, ont constitué une JV